ArticleInternational journal of clinical oncology2020

Emerging RAS, BRAF, and EGFR mutations in cell-free DNA of metastatic colorectal patients are associated with both primary and secondary resistance to first-line anti-EGFR therapy.

Takeshi Yamada et al.PubMed ↗Publisher ↗

No numbers read from the abstract.